Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60,917 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Birring SS, Dicpinigaitis PV, Smith JA, Morice AH, McGarvey LP, Pavord ID, Nguyen AM, Schelfhout J, Li Q, Iskold B, Green SA, Philip G, Muccino DR, La Rosa C. Birring SS, et al. Among authors: li q. Am J Respir Crit Care Med. 2023 Jun 1;207(11):1539-1542. doi: 10.1164/rccm.202211-2128LE. Am J Respir Crit Care Med. 2023. PMID: 36996347 Free PMC article. No abstract available.
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. McGarvey LP, et al. Among authors: li q. Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. Lancet. 2022. PMID: 35248186 Clinical Trial.
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.
Dicpinigaitis PV, Birring SS, Blaiss M, McGarvey LP, Morice AH, Pavord ID, Satia I, Smith JA, La Rosa C, Li Q, Nguyen AM, Schelfhout J, Tzontcheva A, Muccino D. Dicpinigaitis PV, et al. Among authors: li q. Ann Allergy Asthma Immunol. 2023 Jan;130(1):60-66. doi: 10.1016/j.anai.2022.05.003. Epub 2022 May 13. Ann Allergy Asthma Immunol. 2023. PMID: 35569802
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Smith JA, Birring SS, Dicpinigaitis PV, McGarvey LP, Morice AH, Pavord ID, Satia I, Green S, Iskold B, La Rosa C, Li Q, Martin Nguyen A, Schelfhout J, Muccino D. Smith JA, et al. Among authors: li q. Lung. 2022 Aug;200(4):423-429. doi: 10.1007/s00408-022-00553-y. Epub 2022 Jul 27. Lung. 2022. PMID: 35895098 Free PMC article. Clinical Trial.
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB. Reich K, et al. Among authors: li q. Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6. Lancet. 2017. PMID: 28596043 Clinical Trial.
60,917 results
You have reached the last available page of results. Please see the User Guide for more information.